REHOVOT, Israel, Oct. 30, 2020 /PRNewswire/ -- Evogene Ltd. (NASDAQ: EVGN), (TASE: EVGN), a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, today announced that it has entered into definitive agreements with an existing institutional shareholder and certain Israeli institutional investors in connection with a registered direct offering, providing for the issuance of an aggregate of (i) 3.92 million ordinary shares at a purchase price of $2.50 per share, and (ii) 883,534 pre-funded warrants each to purchase one ordinary share ("Pre-Funded Warrants"). The Pre-Funded Warrants will be sold at a price of $2.49 each, with an exercise price of $0.01 per ordinary share. The Pre-Funded Warrants will be exercisable at any time after the date of issuance upon payment of the exercise price.
The offering is expected to result in gross proceeds of $12 million. Evogene intends to use the net proceeds from the offering to further develop its and its subsidiaries' product pipelines, to further enhance and expand its computational predictive biology platform, and for working capital and general corporate purposes.
The offering is expected to close on or before November 3, 2020, subject to customary closing conditions.
Cantor Fitzgerald & Co. is acting as placement agent in the offering.
The ordinary shares and Pre-Funded Warrants offered in the registered direct offering described above are being offered by Evogene pursuant to its shelf registration statement on Form F-3 (File No.333-240249) previously filed and declared effective by the Securities and Exchange Commission (the "SEC") on August 10, 2020. The offering may be made only by means of a prospectus supplement and accompanying prospectus. A prospectus supplement and accompanying prospectus relating to the offering will be filed with the SEC and will be available on the SEC's website at http://www.sec.gov.
This press release is for informational purposes only and should not be construed as investment advice and does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor will there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About Evogene Ltd.:
Evogene (NASDAQ: EVGN), (TASE: EVGN) is a leading computational biology company focused on revolutionizing product discovery and development in multiple life-science based industries, including human health and agriculture, through the use of its broadly applicable Computational Predictive Biology (CPB) platform. The CPB platform, incorporating a deep understanding of biology leveraged through the power of Big Data and Artificial Intelligence, has been designed to computationally discover and uniquely guide the development of life-science products based on microbes, small molecules and genetic elements. Utilizing the CPB platform, Evogene and its subsidiaries are now advancing product pipelines for human microbiome-based therapeutics through Biomica Ltd., medical cannabis through Canonic Ltd., ag-biologicals through Lavie Bio Ltd., ag-chemicals through AgPlenus Ltd., and ag-solutions for castor oil production through Casterra Ltd.
Forward Looking Statements:
This press release contains "forward-looking statements" relating to future events. These statements may be identified by words such as "may", "could", "expects", "intends", "anticipates", "plans", "believes", "scheduled", "estimates", or words of similar meaning. For example, Evogene is using forward-looking statement in this press release when it discusses the intended use of proceeds and closing of the registered direct offering. Such statements are based on current expectations, estimates, projections and assumptions, describe opinions about future events, and involve certain risks and uncertainties which are difficult to predict and are not guarantees of future performance. Therefore, actual future results, performance or achievements of Evogene and its subsidiaries may differ materially from what is expressed or implied by such forward-looking statements due to a variety of factors, many of which are beyond the control of Evogene and its subsidiaries, including, without limitation, the global spread of COVID-19, or the Coronavirus, the various restrictions deriving therefrom and those risk factors contained in Evogene's reports filed with the applicable securities authorities. In addition, Evogene and its subsidiaries rely, and expect to continue to rely, on third parties to conduct certain activities, such as their field-trials and pre-clinical studies, and if these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines (including as a result of the effect of the Coronavirus), Evogene and its subsidiaries may experience significant delays in the conduct of their activities. Evogene and its subsidiaries disclaim any obligation or commitment to update these forward-looking statements to reflect future events or developments or changes in expectations, estimates, projections and assumptions.
Evogene Investor Contact:
Rivka Neufeld
Investor Relations
E: [email protected]
T: +972-8-931-1940
US Investor Relations:
Joseph Green
Edison Group
E: [email protected]
T: +1-646-653-7030
Laine Yonker
Edison Group
E: [email protected]
T: +1-646-653-7035
SOURCE Evogene
Share this article